Loading patent…
OwnerPhilip D. Drew, Rudolf M.T. de Wildt +2inventors
InventorsPhilip D. Drew, Rudolf M.T. de Wildt, Ian M. Tomlinson, Amrik Basran
Estimating the term…
The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1α and/or IL-1β) to the receptor but do not inhibit binding of IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resistand dAb monomers, and to ligands comprising protease resistant dAb monomers. The invention also relates to nucleic acids including vectors that encode the dAb monomers and ligand, to host cells that comprise the nucleic acids and to method for producing a dAb monomer or ligand. The invention also relates to pharmaceutical compositions that comprise the dAb monomers or ligands, and to therapeutic methods that comprise administering a dAb monomer of ligand.
A domain antibody (dAb) monomer that has binding specificity for Interleukin-1 Receptor Type 1 (IL-1R1) and inhibits binding of Interleukin-1 (IL-1) to the receptor but does not inhibit binding of Interleukin-1 Receptor Antagonist (IL-1ra) to IL-1R1.
A ligand comprising a dAb monomer that has binding specificity for IL-1R1 and inhibits binding of IL-1 to the receptor but does not inhibit binding of IL-1ra to IL-1R1, wherein said dAb monomer is selected from the group consisting of DOM4-122-23 (SEQ ID NO:1), and DOM4-122-24 (SEQ ID NO:2).
A ligand comprising a dAb monomer that has binding specificity for IL-1R1 and inhibits binding of IL-1 to the receptor but does not inhibit binding of IL-1ra to IL-1R1, and a dAb monomer that has binding specificity for TNFR1.
57-59. (canceled)
A method for treating an inflammatory disease, arthritis or respiratory disease comprising administering to a subject in need thereof a therapeutically effective amount of a domain antibody (dAb) monomer that is resistant to protease degradation.
Dependencies are inferred from the claim text.